Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$5.71 USD
+0.09 (1.60%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $5.69 -0.02 (-0.35%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AUPH 5.71 +0.09(1.60%)
Will AUPH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for AUPH
Aurinia Announces 2024 Annual General Meeting Results
Aurinia Pharmaceuticals AGM Shareholder Decisions
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Aurinia’s LUPKYNIS Shows Promise for Lupus Nephritis
Aurinia announces presentation on LUPKYNIS at EULAR 2024